Vidac Pharma Secures USPTO Patent for Novel Hexokinase 2-Mitochondrial Interaction Modulators
Key Insights
Vidac Pharma Holdings (search) received a Notice of Issuance from the USPTO (search) on January 8, 2026, for a core patent protecting molecules that modulate hexokinase 2 (search)-mitochondrial interactions.
The patent provides broad protection for up to 20 years from filing date and strengthens the company's intellectual property portfolio around novel small chemical entities targeting HK2 (search).
The company has filed continuation-in-part applications based on the same mechanism to further expand its patent protection in the oncology space.
Vidac Pharma Holdings (search) Plc announced it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO (search)) for one of its core patents, marking a significant milestone in protecting its novel approach to cancer (search) treatment through metabolic pathway modulation. The patent, issued on January 8, 2026, and set for publication on January 20, provides broad protection for molecules that modulate the interaction between hexokinase 2 (search) (HK2 (search)) and mitochondria (search).
Patent Scope and Strategic Value
The granted patent covers a wide range of applications related to developing molecules that target the HK2 (search)-mitochondrial interaction, a critical metabolic checkpoint in cancer (search) cells. According to Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, "This patent issuance represents an important milestone for Vidac Pharma. It strengthens the protection of our novel small chemical entities targeting HK2–mitochondrial interactions."
The patent provides protection for up to 20 years from the filing date, with potential extensions depending on jurisdiction. This intellectual property protection is particularly valuable given the growing scientific recognition of mitochondrial function's role in cellular metabolism and oncology applications.
Expanding Intellectual Property Portfolio
Beyond the newly granted patent, Vidac Pharma has filed continuation-in-part applications based on the same fundamental mechanism identified by its research group. These additional filings aim to further develop and expand the company's intellectual property portfolio around its core therapeutic approach.
The company's strategy focuses on modifying the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 metabolic checkpoint in cancer (search) cells. This approach aims to renormalize the tumor microenvironment and selectively induce programmed cell death without affecting surrounding normal tissue.
Clinical Development Progress
Vidac Pharma's lead drug candidate, VDA-1102, has demonstrated clinical effectiveness in treating advanced actinic keratosis (search) (AK). The compound has also shown promising clinical benefit in interim Phase 2 results for cutaneous T-cell lymphoma (search) (CTCL), highlighting the potential therapeutic applications of the company's HK2 (search)-targeting approach.
The clinical-stage biopharmaceutical company is dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases, positioning itself in the emerging field of metabolic oncology.
Scientific Foundation
Dr. Herzberg emphasized the growing scientific support for their approach, noting that "an increasing body of scientific literature highlights the role of mitochondrial function in cellular metabolism, including in the field of oncology." This scientific foundation supports the company's focus on developing therapeutics that target metabolic pathways in cancer (search) treatment.
The patent protection strengthens Vidac Pharma's position in the competitive landscape of cancer (search) therapeutics, particularly in the area of metabolic pathway modulation, which represents a novel approach to treating various oncologic conditions.